Jami Rubin - 01 Jan 2023 Form 4 Insider Report for EQRx, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
04 Jan 2023, 20:56:56 UTC
Prior SEC filing
27 May 2022
Next SEC filing
01 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ William Collins, Attorney-in-Fact

Key filing fact

Jami Rubin filed Form 4 for EQRx, Inc. on 04 Jan 2023.

Key facts

  • This page summarizes Jami Rubin's Form 4 filing for EQRx, Inc..
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 04 Jan 2023, 20:56.

Change

  • Previous filing in this sequence was filed on 27 May 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EQRX transaction Derivative

Earn-out Shares

Award

Transaction value
Shares
+1,585
Change %
+0.53%
Price
Shares after
302,203
Date
01 Jan 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,585
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 1,585 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 1,109 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 476 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .